Amgen Stock Drops on Tavneos Liver Injury Concerns

Amgen Shares Decline Amid Drug Safety Alarms

Amgen Inc. (NASDAQ:AMGN) shares fell 2.1% following a significant safety warning regarding its drug Tavneos, a treatment for rare kidney diseases. The alert came from Kissei Pharmaceutical, which holds commercialization rights in Japan, citing severe liver injury concerns.

Global Regulatory Scrutiny and Fatalities

Kissei reported 20 fatal cases in Japan associated with the drug, including 13 deaths linked to Vanishing Bile Duct Syndrome. Consequently, the company urged healthcare professionals to stop prescribing Tavneos to new patients. This follows a proposal by the U.S. FDA to withdraw the drug's approval and a review initiated by the European Medicines Agency over data integrity concerns.

Impact on Amgen's Acquisition Strategy

Tavneos was a key asset in Amgen's $16.6 billion acquisition of Horizon Therapeutics in 2023. The escalating safety issues and intense regulatory examination cast significant uncertainty over the drug's future revenue potential and the overall value of the acquisition for Amgen.

Summary

Investors are now closely watching the outcomes of regulatory reviews in the U.S. and Europe. These decisions will be critical in determining the long-term financial impact on Amgen and the viability of Tavneos in major markets.

FAQ

Q: Why did Amgen's stock fall?
A: The stock dropped 2.1% after its Japanese partner, Kissei Pharmaceutical, reported 20 deaths and severe liver injury risks linked to the drug Tavneos.

Q: What is the significance of Tavneos to Amgen?
A: Tavneos is a drug for rare kidney diseases that Amgen acquired as part of its $16.6 billion purchase of Horizon Therapeutics in 2023.

Source: Investing.com